Research Grants - Coalition to Cure Calpain 3
The Coalition to Cure Calpain 3 funds research into the mechanisms, biomarkers, and therapy development for calpainopathy (LGMD2A/R1) through its Research Grants program.
Funder: Coalition to Cure Calpain 3
Due Dates (Anticipated): March 2027
Funding Amounts: Award amounts are variable; typical grants support 1–2 years of research, with budgets matching project scope.
Summary: Supports innovative basic, translational, and clinical research into calpainopathy (LGMD2A/R1), including disease mechanisms, therapy development, and clinical trial readiness.
Key Information: This is a forecasted opportunity; no standing open call—contact the funder to discuss project fit.
Description
The Coalition to Cure Calpain 3 (C3) offers research grants to advance the understanding and treatment of calpainopathy (LGMD2A/R1), a rare muscular dystrophy caused by mutations in the CAPN3 gene. The program funds a broad spectrum of projects, including basic mechanistic studies, drug screening, gene therapy development, biomarker discovery, and efforts to optimize clinical trial readiness. Grants are intended to foster both foundational and translational research that can lead to effective therapies for individuals affected by calpain 3-related muscular dystrophies.
